Genetic Syndromes and Radiotherapy in Breast Cancer

  • Camille Green
  • Atif J. Khan
  • Bruce G. Haffty
Part of the Medical Radiology book series (MEDRAD)


In this article, the controversial issue of breast-conserving therapy (lumpectomy followed by whole breast irradiation) is reviewed. Given the relatively recent identification of the BRCA1 and BRCA2 genes in the mid-1990s, the expense associated with testing, and the inherent selection biases, the available literature has inherent limitations with relatively small patient numbers and lack of prospective randomized trials in this subset of patients. However, a number of retrospective and case–control studies have demonstrated acceptable results with breast-conserving surgery and radiation, though without active prophylactic measures to reduce secondary malignancies late local in-breast relapses and contralateral secondary breast cancer events remain an issue. Acknowledging the limitations in the available data, there does not appear to be any evidence of compromised normal tissue reactions or compromised long-term survival rates in women electing breast-conserving surgery and radiation.


Breast Cancer Cystic Fibrosis Transmembrane Conductance Regulator Contralateral Breast Cancer Breast Conservation Therapy BRCA Carrier 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abeliovich D, Kaduri L, Lerer I et al (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60 percent of ovarian cancer and 30 percent of early-onset breast cancer patients among Ashkenazi Jewish women. Am J Hum Genet 60:505PubMedCentralPubMedGoogle Scholar
  2. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J (2000) Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 6:3923–3931PubMedGoogle Scholar
  3. Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308CrossRefPubMedCentralGoogle Scholar
  4. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D (1998) Survival in early-onset BRCA1 breast-cancer patients. Institute Curie Breast Cancer Group. Lancet 352:541CrossRefPubMedGoogle Scholar
  5. Balia C, Sensi E, Lombardi G, Roncella M, Bevilacqua G, Caligo MA (2010) PALB2: a novel inactivating mutation in a Italian breast cancer family. Fam Cancer 9:531–536CrossRefPubMedGoogle Scholar
  6. Bell DW, Kim SH, Godwin AK et al (2007) Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 121:2661–2667CrossRefPubMedCentralPubMedGoogle Scholar
  7. Bertheau P, Turpin E, Rickman DS et al (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4:e90CrossRefPubMedCentralPubMedGoogle Scholar
  8. Blichert-Toft M (1992) Breast-conserving therapy for mammary carcinoma: psychosocial aspects, indications, and limitations. Ann Med 24(6):445–451CrossRefPubMedGoogle Scholar
  9. Blichert-Toft M, Rose C, Andersen JA et al (1992) Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish breast cancer cooperative group. J Natl Cancer Inst Monogr 11:19–25PubMedGoogle Scholar
  10. Brandburg Y, Sandelin K, Erikson S et al (2008) Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high-risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 26:3943–3949CrossRefGoogle Scholar
  11. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C et al (2007) Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43:867–876CrossRefPubMedGoogle Scholar
  12. Bremer M, Klopper K, Yamini P, Bendix-Waltes R, Dork T, Karstens JH (2003) Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother Oncol 69:155–160CrossRefPubMedGoogle Scholar
  13. Brennan K, Garcias-Closas M, Orr N et al (2012) Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res 72(9):2304–2313CrossRefPubMedGoogle Scholar
  14. Broeks A, de Witte L, Nooijen A et al (2004) Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 83:91–93CrossRefPubMedGoogle Scholar
  15. Brooks JD, Teraoka SN, Reiner AS et al (2012) Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study. Hum Mutat 33:158–164CrossRefPubMedCentralPubMedGoogle Scholar
  16. Chappuis PO, Nethercot V, Foulkes WD (2000) Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18:287–295CrossRefPubMedGoogle Scholar
  17. Chehab NH, Malikzay A, Appel M, Halazonetis TD (2000) Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14:278–288PubMedCentralPubMedGoogle Scholar
  18. Clark RM, Whelan T, Levine M et al (1996) Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario clinical oncology group. J Natl Cancer Inst 88:1659–1664CrossRefPubMedGoogle Scholar
  19. Ding YC, Steele L, Chu LH et al (2011) Germline mutations in PALB2 in African-American breast cancer cases. Breast Cancer Res Treat 126:227–230CrossRefPubMedCentralPubMedGoogle Scholar
  20. Edvardsen H, Tefre T, Jansen L et al (2007) Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence. Radiat Oncol 2:25CrossRefPubMedCentralPubMedGoogle Scholar
  21. Fisher B, Anderson S (1994) Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National surgical adjuvant breast and bowel project. World J Surg 18:63–69CrossRefPubMedGoogle Scholar
  22. Fisher B, Anderson S, Bryant J et al (2002a) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med 347:1233–1241CrossRefPubMedGoogle Scholar
  23. Fisher B, Bryant J, Dignam JJ et al (2002b) Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141–4149CrossRefPubMedGoogle Scholar
  24. Fitzgerald M, MacDonald D, Krainer M, Additional A, Additional A, Additional A (1996) Germline BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996:143CrossRefGoogle Scholar
  25. Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471–1477CrossRefPubMedGoogle Scholar
  26. Hirao A, Kong YY, Matsuoka S et al (2000) DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287:1824–1827CrossRefPubMedGoogle Scholar
  27. Ho AY, Atencio DP, Peters S et al (2006) Genetic predictors of adverse radiotherapy effects: the gene-PARE project. Int J Radiat Oncol Biol Phys 65:646–655CrossRefPubMedGoogle Scholar
  28. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J (2009) High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 69:3625–3633CrossRefPubMedGoogle Scholar
  29. Kandioler-Eckersberger D, Ludwig C, Rudas M et al (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50–56PubMedGoogle Scholar
  30. Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A (2005) Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41:2304–2311CrossRefPubMedGoogle Scholar
  31. Knappskog S, Lonning PE (2012) P53 and its molecular basis to chemoresistance in breast cancer. Expert Opin Ther Targets 16(Suppl 1):S23–S30CrossRefPubMedGoogle Scholar
  32. Kulkarni DA, Vazquez A, Haffty BG et al (2009) A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis 30:1910–1915CrossRefPubMedCentralPubMedGoogle Scholar
  33. Liljegren G, Holmberg L, Bergh J et al (1999) 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol 17:2326–2333PubMedGoogle Scholar
  34. Linde L, Boelz S, Nissim-Rafinia M et al (2007) Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 117:683–692CrossRefPubMedCentralPubMedGoogle Scholar
  35. Long J, Cai Q, Sung H et al (2012) Genome-wide association study in East asians identifies novel susceptibility Loci for breast cancer. PLoS Genet 8:e1002532CrossRefPubMedCentralPubMedGoogle Scholar
  36. Lonning PE (2004) Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance. Trends Mol Med 10:113–118CrossRefPubMedGoogle Scholar
  37. Matsuoka S, Huang M, Elledge SJ (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282:1893–1897CrossRefPubMedGoogle Scholar
  38. Metcalfe K, Lubinski J, Ghadirian P et al (2008) Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the hereditary breast cancer clinical study group. J Clin Oncol 26:1093–1097CrossRefPubMedGoogle Scholar
  39. Mock V (1993) Body image in women treated for breast cancer. Nurs Res 42:153–157CrossRefPubMedGoogle Scholar
  40. Mort M, Ivanov D, Cooper DN, Chuzhanova NA (2008) A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat 29:1037–1047CrossRefPubMedGoogle Scholar
  41. Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary breast cancer clinical study group. Lancet 356:1876–1881CrossRefPubMedGoogle Scholar
  42. Pierce LJ, Strawderman M, Narod SA et al (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18:3360–3369PubMedGoogle Scholar
  43. Pierce LJ, Levin AM, Rebbeck TR et al (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437–2443CrossRefPubMedGoogle Scholar
  44. Pierce LJ, Phillips KA, Griffith KA et al (2010) Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 121:389–398CrossRefPubMedCentralPubMedGoogle Scholar
  45. Poggi MM, Danforth DN, Sciuto LC et al (2003) Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National cancer institute randomized trial. Cancer 98:697–702CrossRefPubMedGoogle Scholar
  46. Pollard JM, Gatti RA (2009) Clinical radiation sensitivity with DNA repair disorders: an overview. Int J Radiat Oncol Biol Phys 74:1323–1331CrossRefPubMedCentralPubMedGoogle Scholar
  47. Rebbeck TR (2000) Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 18:100S–103SPubMedGoogle Scholar
  48. Rebbeck T, Friebel T, Lynch H et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22:1055CrossRefPubMedGoogle Scholar
  49. Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115–123CrossRefPubMedGoogle Scholar
  50. Renwick A, Thompson D, Seal S et al (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38:873–875CrossRefPubMedGoogle Scholar
  51. Robson M, Levin D, Federici M et al (1999) Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112–2117CrossRefPubMedGoogle Scholar
  52. Robson ME, Boyd J, Borgen PI, Cody HS 3rd (2001) Hereditary breast cancer. Curr Probl Surg 38:387–480CrossRefPubMedGoogle Scholar
  53. Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17CrossRefPubMedCentralPubMedGoogle Scholar
  54. Robson M, Svahn T, McCormick B et al (2005a) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 103:44–51CrossRefPubMedGoogle Scholar
  55. Robson M, Svahn T, McCormick B et al (2005b) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 103:44–51CrossRefPubMedGoogle Scholar
  56. Savitsky K, Bar-Shira A, Gilad S et al (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749–1753CrossRefPubMedGoogle Scholar
  57. Schain W, D’Angelo T, Dunn M et al (1994) Mastectomy versus conservative surgery and radiation therapy: psychosocial consequences. Cancer 73(4):1221–1228CrossRefPubMedGoogle Scholar
  58. Seppala EH, Ikonen T, Mononen N et al (2003) CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 89:1966–1970CrossRefPubMedCentralPubMedGoogle Scholar
  59. Seynaeve C, Verhoog LC, Van De Bosch LM et al (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40:1150–1158CrossRefPubMedGoogle Scholar
  60. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C (2000) The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14:289–300PubMedCentralPubMedGoogle Scholar
  61. Smith BD, Arthur DW, Buchholz TA et al (2009) Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 74:987–1001CrossRefPubMedGoogle Scholar
  62. Steinmann D, Bremer M, Rades D et al (2001) Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer 85:850–858CrossRefPubMedCentralPubMedGoogle Scholar
  63. Tassone P, Tagliaferri P, Perricelli A et al (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285–1291CrossRefPubMedCentralPubMedGoogle Scholar
  64. The Breast Cancer Linkage Consortium (1999) BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316CrossRefGoogle Scholar
  65. Tischkowitz M, Capanu M, Sabbaghian N et al (2011) Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat 33:674–680CrossRefGoogle Scholar
  66. Turnbull C, Seal S, Renwick A et al (2012) Gene-gene interactions in breast cancer susceptibility. Hum Mol Genet 21:958–962CrossRefPubMedCentralPubMedGoogle Scholar
  67. van Dongen JA, Voogd AC, Fentiman IS et al (2000) Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst 92:1143–1150CrossRefPubMedGoogle Scholar
  68. Venkitaraman A (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171CrossRefPubMedGoogle Scholar
  69. Verhoef L, Stalpers L, Verbeek A, Wobbes T, van Daal W (1991) Breast-conserving treatment or mastectomy in early breast cancer: a clinical decision analysis with special reference to the risk of local recurrence. Eur J Cancer 27:1132–1137CrossRefPubMedGoogle Scholar
  70. Veronesi U, Marubini E, Mariani L et al (2001) Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 12:997–1003CrossRefPubMedGoogle Scholar
  71. Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227–1232CrossRefPubMedGoogle Scholar
  72. Vrieling C, Collette L, Fourquet A et al (1999) The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC “boost versus no boost” trial. EORTC radiotherapy and breast cancer cooperative groups. European organization for research and treatment of cancer. Int J Radiat Oncol Biol Phys 45:677–685CrossRefPubMedGoogle Scholar
  73. Vrieling C, Collette L, Fourquet A et al (2000) The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC radiotherapy and breast cancer cooperative groups. Radiother Oncol 55:219–232CrossRefPubMedGoogle Scholar
  74. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14:927–939PubMedCentralPubMedGoogle Scholar
  75. Wilschanski M, Famini C, Blau H et al (2000) A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161:860–865CrossRefPubMedGoogle Scholar
  76. Winzer KJ, Sauer R, Sauerbrei W et al (2004) Radiation therapy after breast-conserving surgery; first results of a randomised clinical trial in patients with low risk of recurrence. Eur J Cancer 40:998–1005CrossRefPubMedGoogle Scholar
  77. Zhang F, Ma J, Wu J et al (2009) PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 19:524–529CrossRefPubMedCentralPubMedGoogle Scholar
  78. Zhao L, Gu A, Ji G, Zou P, Zhao P, Lu A (2012) The association between ATM IVS 22-77 T>C and cancer risk: a meta-analysis. PLoS One 7:e29479CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Camille Green
    • 1
  • Atif J. Khan
    • 1
  • Bruce G. Haffty
    • 1
  1. 1.Department of Radiation OncologyUMDNJ-RWJMS, Cancer Institute of New JerseyNew BrunswickUSA

Personalised recommendations